Aummune Overview

  • Founded
  • 2017
  • Status
  • Private
  • Latest Deal Type
  • Early Stage VC
  • Investors
  • 1

Aummune General Information


Developer of cancer therapeutics intended to provide personalized patient-specific disease parameters at each stage of the therapeutic pathway. The company's therapeutics addresses the unmet need for highly personalized, targeted, safe and agile therapies for widespread, life-threatening diseases, enabling cancer patients to transform their lives through therapeutics by revolutionising the way in which cancer, antibiotic-resistant bacteria and viruses are treated medically.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Tel Aviv Medical Center (TAMC)
  • Sammy Ofer Building - Floor 10, 6 Weizmann Street
  • Tel Aviv
  • Israel
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Aummune Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 01-Jan-2017 Completed Startup
To view Aummune’s complete valuation and funding history, request access »

Aummune Executive Team (5)

Name Title Board Seat Contact Info
Guy Neev Co-Founder & Chief Executive Officer
Ido Bachelet Chief Technology Officer
Raanan Berger Ph.D Chief Marketing Officer
Irit Carmi-Levy Ph.D Chief Scientific Officer
Marius Nacht Co-Founder
To view Aummune’s complete executive team members history, request access »

Aummune Board Members (1)

Name Representing Role Since
Yair Schindel MD aMoon Fund Chairman 000 0000
To view Aummune’s complete board members history, request access »

Aummune Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
aMoon Fund Venture Capital Minority 000 0000 000000 0
To view Aummune’s complete investors history, request access »